Earnings ·
AstraZeneca reported H1 2026 total revenue of $30.67 billion, up 9% actual and 6% at constant exchange rates (CER)…
AZNCFAstrazeneca PLC
AstraZeneca reported H1 2026 total revenue of $30.67 billion, up 9% actual and 6% at constant exchange rates (CER), and Q2 2026 total revenue of $15.38 billion, up 6% actual and 5% CER. Core EPS for H1 2026 rose 12% to $5.21, while Q2 2026 Core EPS increased 21% to $2.63. The company increased its interim dividend by 3 cents to $1.06 per share and reconfirmed its FY 2026 guidance for mid-to-high single-digit total revenue growth and low double-digit Core EPS growth at CER. AstraZeneca is a pharmaceutical company that develops and sells innovative medicines. { "split": null }